Treatment of Antibody-Mediated Rejection (ABMR) With CarBel

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-01-15

Study Completion Date

2027-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to see:

1. If using these two drugs (carfilzomib and belatacept) together is safe
2. If the use of these two study drugs in addition to the usual immunosuppression for kidney transplant patients can improve your transplanted kidney function by lowering the antibodies you have against your transplanted kidney
3. If the study drugs effect the immune cells that were responding to your donor kidney. And, whether blood or urine tests can measure signs of inflammation and kidney cell injury
4. If using new computer techniques can help describe important changes seen on biopsy in your donated kidneys

The primary objective is to assess the efficacy of carfilzomib and belatacept therapy when added to current treatment with steroids and maintenance immunosuppression, compared to conventional treatment alone, to improve the clinical outcome of renal transplant patients with active and chronic - active ABMR occurring more than 6 months after renal transplantation or less than 6 months post-transplant with persistent refractory Antibody-Mediated Rejection (ABMR)

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Kidney Transplant Rejection

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Carfilzomib Kidney transplant Belatacept

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Investigational Treatment Arm

Study Entry to Month-3 participants will receive:

* Steroid pulse/taper
* Kyprolis® (Carfilzomib)
* Nulojix® (Belatacept)
* Tacrolimus
* Mycophenolate
* Prednisone

After 3 months participants will receive:

* Belatacept +
* Mycophenolate
* Prednisone
* Tacrolimus

Group Type EXPERIMENTAL

Carfilzomib

Intervention Type BIOLOGICAL

Administered by intravenous infusion over 60 minutes.

Belatacept

Intervention Type BIOLOGICAL

Administered by intravenous infusion over 30 minutes.

Conventional Treatment Arm

Study Entry to Month-3 participants will receive:

* Steroid pulse/taper
* Intravenous Immunoglobulin (IVIG)
* Tacrolimus OR Belatacept +
* Mycophenolate
* Prednisone

After 3 months participants will receive:

* Kyprolis® (Carfilzomib)
* Nulojix ® (Belatacept)
* Tacrolimus
* Mycophenolate
* Prednisone

After an additional 3 months (6 months from study entry) participants will receive:

* Belatacept +
* Mycophenolate
* Prednisone
* Tacrolimus

Group Type EXPERIMENTAL

Carfilzomib

Intervention Type BIOLOGICAL

Administered by intravenous infusion over 60 minutes.

Belatacept

Intervention Type BIOLOGICAL

Administered by intravenous infusion over 30 minutes.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Carfilzomib

Administered by intravenous infusion over 60 minutes.

Intervention Type BIOLOGICAL

Belatacept

Administered by intravenous infusion over 30 minutes.

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Kyprolis Nulojix

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Able to understand and agree to participate in the study.
2. Have received a kidney transplant from a living or deceased donor (including re-transplants).
3. Men and women must agree to use birth control during the study and for 3 months after the last dose of study drugs, or be surgically sterile or post-menopausal.
4. Heart function must be good enough (LVEF of at least 40%) without severe heart issues or high blood pressure in the lungs.
5. Must have been previously exposed to the Epstein-Barr Virus (EBV).
6. Diagnosed with specific types of kidney transplant rejection based on criteria, with certain conditions on timing and treatment history.
7. Kidney function must be at a certain level (eGFR of at least 30 ml/min/1.73 m²).
8. Specific scores related to kidney biopsy results must be within certain limits.
9. Must have a measurable level of specific antibodies against the donor kidney (HLA DSA) with a certain intensity.
10. Up-to-date vaccinations according to guidelines for transplant patients.
11. Must have a negative tuberculosis (TB) test and chest x-ray before enrollment, no symptoms or known contact with TB, and not have recently traveled to or lived in areas with high TB rates. If previously infected with TB, must have completed treatment and have a recent negative chest x-ray.
12. If previously infected with COVID-19, must be fully recovered for at least 21 days before joining the study. No COVID-19 test required for those without symptoms.

Exclusion Criteria

1. Unable or unwilling to give consent or follow study rules.
2. Kidney transplant with incompatible blood types.
3. Very high levels of protein in urine, indicating severe kidney issues.
4. Previously had a non-kidney organ or bone marrow transplant.
5. Any other medical issues that might increase risk, make following the study rules hard, or affect study results, as judged by the study doctor.
6. Heart attack within the last year, uncontrolled chest pain, or signs of a recent heart problem on an ECG.
7. Severe heart failure (Class 3 or higher).
8. Irregular heartbeats that can't be controlled with medication.
9. Used any experimental drug within the last 4 weeks or longer if the drug stays in the body longer.
10. Serious medical or mental health issues that could interfere with the study.
11. Cancer diagnosis or treatment within the past 2 years, except for certain skin cancers or cancers with a high cure rate.
12. Known allergy to Captisol® (used in the study drug).
13. Very low blood counts (hemoglobin, neutrophils, or platelets).
14. Positive for HIV, Hepatitis B, or Hepatitis C, unless Hepatitis C was successfully treated.
15. Severe infections needing treatment in the last 4 weeks.
16. Specific kidney infection (BK nephropathy) or high levels of BK virus.
17. Certain kidney biopsy results indicating other types of rejection or kidney diseases.
18. Treated for a specific viral infection (CMV) in the last 90 days or resistant to certain CMV treatments.
19. Received a live vaccine in the last 4 weeks.
20. Severe liver disease or abnormal liver tests.
21. Pregnant or breastfeeding women. Women who can become pregnant must have a negative pregnancy test or proof they are not pregnant.
22. Any other significant medical condition that could interfere with the study according to the doctor.
23. Received certain antibody treatments in the last 3 months.
24. Kidney rejection within 6 months post-transplant without standard care.
25. Confirmed severe protein levels in urine.
26. Underwent certain treatments outside study criteria.
27. History of multiple unprovoked blood clots.
28. Diagnosed with Atypical Hemolytic Uremic Syndrome (aHUS).

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Stuart J Knechtle, M.D.

Role: PRINCIPAL_INVESTIGATOR

Duke University Medical Center: Transplantation

Scott Sanoff, MD, Ph.D.

Role: STUDY_CHAIR

Duke University Medical Center: Transplantation

Locations

Explore where the study is taking place and check the recruitment status at each participating site.